TLX trades 100.9% below Wall Street's consensus target of $18.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TLX achieves its forward estimates and maintains a stable P/E multiple of 73.7x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Telix Pharmaceuticals Limited (TLX) has a Wall Street consensus price target of $18.00, based on estimates from 5 covering analysts. With the stock currently trading at $8.96, this represents a potential upside of +100.9%. The company has a market capitalization of $3.04B.
Analyst price targets range from a low of $18.00 to a high of $18.00, representing a 0% spread in expectations. The median target of $18.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TLX trades at a trailing P/E of -432.9x and forward P/E of 73.7x.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $2.21, with bear and bull scenarios of $1.39 and $2.91 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EXELExelixis, Inc. | $17.2B | $68.29 | $53.00 | -22.4% | Hold | 18.4x | 33 |
RNWReNew Energy Global Plc | $2.5B | $6.96 | $7.02 | +0.9% | Buy | 0.5x | 6 |
AGENAgenus Inc. | $267M | $6.40 | $25.00 | +290.6% | Buy | 23.9x | 12 |
LNTHLantheus Holdings, Inc. | $6.6B | $102.00 | $102.65 | +0.6% | Buy | 19.0x | 19 |
NVSNovartis AG | $295.0B | $155.21 | $149.50 | -3.7% | Hold | 17.5x | 25 |
BMYBristol-Myers Squibb Company | $121.6B | $59.56 | $66.08 | +10.9% | Hold | 9.2x | 42 |
PRAXPraxis Precision Medicines, Inc. | $8.5B | $305.19 | $611.69 | +100.4% | Buy | — | 18 |
GEGE Aerospace | $340.4B | $328.10 | $385.00 | +17.3% | Buy | 40.2x | 36 |
GEHCGE HealthCare Technologies Inc. | $37.8B | $83.66 | $81.14 | -3.0% | Buy | 16.7x | 20 |
SYKStryker Corporation | $122.0B | $318.15 | $354.47 | +11.4% | Buy | 21.4x | 52 |
Quick answers to the most common questions about buying TLX stock.
The consensus Wall Street price target for TLX is $18, representing 100.9% upside from the current price of $8.96. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TLX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $18 implies 100.9% upside from current levels.
At a forward P/E of 73.7449x, TLX trades at a premium valuation. The consensus price target of $18 (100.9% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $18 for TLX, while the most conservative target is $18. The consensus of $18 represents the median expectation. Our quantitative valuation model projects a bull case target of $3 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
TLX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TLX stock forecast based on 5 Wall Street analysts shows a consensus price target of $18, with estimates ranging from $18 (bear case) to $18 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $2, with bear/bull scenarios of $1/$3.
Our quantitative valuation model calculates TLX's fair value at $2 (base case), with a bear case of $1 and bull case of $3. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
TLX trades at a forward P/E ratio of 73.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on TLX, with a "Buy" consensus rating and $18 price target (100.9% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TLX analyst price targets range from $18 to $18, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18 consensus represents the middle ground. Our model's $1-$3 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.